Traders should watch for potential downward pressure on the stock; coordinated C-suite selling at high magnitude relative to typical patterns may indicate private concerns about valuation or upcoming catalysts. Monitor for further filings or news that could clarify intent.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $65.42entry
- T+1 · 7mo ago +1.97%α +0.76% · $66.71
- T+5 · 7mo ago +0.09%α −0.88% · $65.48
- T+20 · 6mo ago +20.21%α +13.58% · $78.64
- T+60 · 4mo ago +25.24%α +18.09% · $81.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top executives at Cytokinetics, including the CEO and Chief Commercial Officer, sold nearly $1 million in shares over a single day, with both transactions occurring at market prices. This coordinated open-market selling by C-suite leaders signals potential lack of confidence in near-term prospects despite no disclosed negative news.
Key Financial Metrics
Key Facts
- CEO Robert Blum sold 7,500 shares for $490,350 at $65.38 per share on April 15, 2026
- EVP Andrew Callos sold 7,449 shares for $491,782.98 at $66.02 per share on April 15, 2026
- Total insider selling in the cluster: $982,132.98 over a 7-day window
- Both transactions were open-market sales (code S), not tax-related or automatic disposals
Financial Impact
$982,133 in open-market share sales by two C-suite executives
Risk Factors
- Perception of insider pessimism could erode investor confidence
- Potential for follow-on selling if other insiders act similarly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1776288585732 |
Track record
46 reports on CYTK
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers